News

Although this approval is good news for Merck, and for many patients, the new stroke risk indication is based on the landmark LIFE trial, which indicated that this

In June 2003, Curis established a collaboration with Genentech for the development of a set of technologies based on inhibition of the Hedgehog signaling pathway, including small molecule

In this phase IIa clinical trial, valopicitabine (NM283) in combination with pegylated interferon was evaluated in treatment-naive genotype 1 hepatitis C patients. In the trial, nine patients receiving

Bionaut will provide a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel pathway reporter system to

Carboplatin is one of the most broadly used anticancer agents. The exclusivity for Bristol-Myers Squibb’s Paraplatin expired in 2004, after which generic versions of the product were approved.

These are the first targets to be selected for advancement in the strategic collaboration established last year between Celera Genomics and Abbott to discover, develop and commercialize therapies

The patent held for Zyprexa had been challenged by generics manufacturers Dr Reddy’s, Ivax Corp and Teva Pharmaceuticals. The ruling to uphold Lilly’s intellectual property, made in a

Following Cenes’ innovative research program that began in 2003, the two companies have been working together and have identified several series of novel compounds active against the clinically

Preliminary findings from two placebo-controlled human studies on two formulations of M.doc, a haemostatic agent for wound care, indicate that there were no adverse affects and no safety